Trade BeyondSpring Inc. - BYSI CFD

BeyondSpring Inc. Company profile

About Beyondspring Inc

BeyondSpring Inc. is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

Financial summary

BRIEF: For the nine months ended 30 September 2021,Beyondspring Inc revenues increased from $0K to $1M. Netloss increased 26% to $54.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing increase from $10.2Mto $22M (expense), Stock-based Compensation in SGA increaseof 76% to $3.7M (expense).